In Vivo Investigations on the Role of the Kinin System in Tissue Injury and Shock Syndromes

  • D. Urbanitz
  • R. Sailer
  • E. Habermann
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 8)


The kinin system works well in vitro; its activation in vivo has been generally accepted. In older (7) and recent (4) reviews of a series of processes are enumerated in which the kinin system could be involved: functional hyperemia, especially of salivary glands, reactions to heat and to local injury, antidromic vasodilatation, circulatroy shock and related phenomena, allergic reactions, carcinoid syndrome, hereditary angioneurotic edema, gouty arthritis. Today, many of earlier theories have been doubted (for review see (5)). In order to gain fundaments for further biochemical research, we tried some experiments promising clear-cut answers to the following questions.


Carcinoid Syndrome Gouty Arthritis Kinin Activity Sodium Oxalate Kinin Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aarsen, P. N.: Brit. J. Pharmacol. 32, 453 (1968).PubMedGoogle Scholar
  2. 2.
    Diniz, C. R., J. F. Carvalho, J. Ryan, M. Rocha e Silva: Nature, 192, 1194(1961).Google Scholar
  3. 3.
    Folk, J. E., K. A. Piez, W. R. Carrol, J. A. Gladner: J. Biol. Chem., 235, 2272(1960).Google Scholar
  4. 4.
    Frey, E. K., H. Kraut, E. Werle: Das Kallikrein-Kinin-system und seine Inhibitoren: Ferdinand Enke Verlag Stuttgart, 1968.Google Scholar
  5. 5.
    Habermann, E.: In: Neue Aspekte der Trasylol Therapie, 3, 37 (1968). F. K. Schattauer Verlag Stuttgart-New York.Google Scholar
  6. 6.
    Habermann, E.: In: Heffter-Heubner Hdb. exper. Pharmakol., In press.Google Scholar
  7. 7.
    Lewis, G. P.: Physiol. Rev., 40, 647 (1960).PubMedGoogle Scholar
  8. 8.
    Majno, G., G. E. Palade: J. Biophys. Biochem. Cyt., 11, 571 (1961).CrossRefGoogle Scholar
  9. 9.
    Rocha e Silva, M., A. Antonio: Med. exper., 3, 371 (1960).Google Scholar
  10. 10.
    Starr, M. S., G. B. West: Brit. J. Pharmacol., 31, 178 (1967).PubMedGoogle Scholar
  11. 11.
    Urbanitz, D., H. Wiegand, E. Habermann: Naunyn Schmiedeberg1 s Arch. Pharmakol. exp. Path., 263, 280(1969).Google Scholar
  12. 12.
    Urbanitz, D., H. Wiegand, E„ Habermann: Nauyn Schmiedeberg’s Arch. Pharmakol. exp. Path., In press.Google Scholar
  13. 13.
    Vane, J. R.: Brit. J. Pharmacol., 35, 209(1969).Google Scholar
  14. 14.
    Wilhelm, D. L.: Pharmacol. Rev., 14, 251 (1962).PubMedGoogle Scholar
  15. 15.
    Yang, H. Y. T., E. G. Erdos: Nature, 215, 1402 (1967).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1970

Authors and Affiliations

  • D. Urbanitz
    • 1
  • R. Sailer
    • 1
  • E. Habermann
    • 1
  1. 1.Pharmacological Institute63 GiessenGermany

Personalised recommendations